7/102 sources · 2 publishersUpdated Oct 8, 22:21 UTC
ViiV Healthcare reports Phase IIIb CROWN trial results for Cabenuva
ViiV Healthcare, a GSK subsidiary, announced that its long‑acting HIV regimen Cabenuva met the primary endpoint in the Phase IIIb CROWN study. The trial showed that the injectable combination achieved superior viral suppression compared with daily oral therapy in participants with detectable HIV‑1. The company said the results address an evidence gap for patients who have not yet achieved suppression on oral antiretroviral therapy.
Why it matters
If regulators approve Cabenuva for this new indication, the product could reach a broader patient base and boost GSK's HIV portfolio, according to the company's statement.
Key facts
- 1The CROWN trial met its primary endpoint, demonstrating non‑inferiority to standard of care. seekingalpha.com
- 2The study reported superior viral suppression versus daily oral therapy at six months. indianpharmapost.com
- 3One source says the trial enrolled about 326 adults and adolescents across 85 sites in eight countries. indianpharmapost.com
- 4Another source states the Phase IIIb CROWN trial involved 1,190 participants. seekingalpha.com
- 5Cabenuva is currently approved in the United States and other markets for virologically suppressed patients. indianpharmapost.com
- 6Use of Cabenuva in patients with detectable viremia remains investigational and has not yet received regulatory approval. indianpharmapost.com
Open questions
- Conflicting participant counts: 1,190 vs about 326.
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.